Lilly says more than 20,000 patients started oral GLP-1 Foundayo since April launch
About a third of prescribers had never written a GLP-1 before, and 45% of users bought the pill through LillyDirect, executives told investors.
MH
By Maren Holt · Senior Reporter, GLP-1
Apr 30 03:00 ETSource: IndyStar
The wire
- 01Lilly disclosed on its April 30 call that over 20,000 people are taking Foundayo, the once-daily oral GLP-1 broadly launched April 9 after FDA approval the prior week.
- 02Two of the three major US pharmacy benefit managers will cover Foundayo by mid-May, some Medicare patients gain access July 1 via a bridge program, and insured patients may pay as little as $25 a month through Amazon.
- 03Uptake figures come from the company; whether new prescribers and direct-to-consumer buyers persist beyond the launch window is unknown.
From the source
Read at indystar.comMore than 20k people on oral GLP-1 pill as Eli Lilly ramps up access
More than 20,000 people are taking Eli Lilly's new GLP-1 weight loss pill approved earlier this month, and company executives expect that number to keep growing as Lilly continues its hold on the weight loss drug market.